1 Forward-Looking Statements 2 • This presentation, including any oral presentation accompanying it, contains "forward-looking statements," including statements about Lexicon's strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as projections of our future results of operations or of our financial condition, the potential therapeutic and commercial potential of pilavapadin (LX9211), LX9851, sotagliflozin and our other drug programs, the ...

Cross Asset Research 10 June 2025 European Pharmaceuticals & Life Sciences On the Road in China: Accelerating Biopharma Innovation and Business Development Opportunities China's biopharma sector is regaining momentum, driven by rising innovation & renewed deal activity with MNC partners. We report key takeaways from our field trip, highlighting both near-term BD opportunities and long-term strategic relevance of the region; we see OW-rated AZN and SAN as LT winners. Listen Our recent two-week visit to China ...

J P M O R G A N Asia Pacific Equity Research 30 May 2025 This material is neither intended to be distributed to Mainland China investors nor to provide securities investment consultancy services within the territory of Mainland China. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan. China healthcare Where is HSHCI from a historical perspective Two news items got our attention on May 29th. The news that the US Court of International T ...